CVRx achieved key foundational goals in 2025, with total revenue for Q4 2025 reaching $16.0 million, a 4% increase over the prior year quarter. The company also initiated the BENEFIT-HF trial and saw new Category I CPT codes take effect, positioning it for accelerated growth in 2026.

CVRx delivered solid second quarter results, with total revenue reaching $13.6 million, a 15% increase year-over-year. The company saw continued growth in its U.S. Heart Failure business, driven by expansion into new sales territories and increased awareness of Barostim. Despite an increase in operating expenses, the company's gross profit also grew by 16%.

CVRx, Inc. announced its first quarter 2025 financial and operating results, reporting a total revenue of $12.3 million, a 15% increase year-over-year. The company significantly reduced its net loss to $13.8 million from $22.2 million in the prior year, driven by decreased operating expenses, particularly in selling, general, and administrative costs. Active implanting centers grew to 227, and real-world evidence supported Barostim's effectiveness in reducing hospital visits.

CVRx reported a 36% increase in revenue to $15.3 million for the fourth quarter of 2024, driven by a 39% increase in U.S. revenue. The company's net loss was $10.7 million, or $0.43 per share.

CVRx reported a 27% increase in revenue for Q3 2024, driven by growth in the U.S. heart failure business. The company saw increases in active implanting centers and sales territories. Gross profit also increased, while R&D expenses decreased. The company expects revenue between $14.5 million and $15.5 million for the fourth quarter of 2024.

CVRx reported a 24% increase in revenue to $11.8 million for Q2 2024, driven by a 29% increase in U.S. revenue. The company's gross profit was $9.9 million, with a gross margin of 84%. Net loss was $14.0 million, or $0.65 per share. The company strengthened its executive team to drive market development priorities.

CVRx reported a 35% increase in revenue to $10.8 million for Q1 2024 compared to Q1 2023. The U.S. revenue increased by 42% to $9.8 million, driven by growth in the U.S. HF business. However, the company experienced commercial execution challenges in the U.S. Heart Failure business during a management transition.

CVRx reported a strong fourth quarter with a 58% increase in revenue compared to the same period last year, driven primarily by growth in the U.S. heart failure market. The company also highlighted key achievements such as Barostim labeling expansion and CMS' OPPS ruling.

CVRx reported a strong third quarter in 2023, with revenue increasing by 70% to $10.5 million, driven primarily by a 90% increase in U.S. revenue. The company is focused on maintaining positive momentum and reducing quarterly cash burn. Active implanting centers increased to 159, and gross margin improved to 84%.

CVRx reported an 89% increase in revenue to $9.5 million for Q2 2023, driven by a 111% increase in U.S. revenue. Gross profit increased by 108% to $8.0 million, with a gross margin of 84%. Net loss was $11.7 million, or $0.56 per share.

CVRx reported a strong first quarter in 2023, with revenue reaching $8.0 million, a 96% increase compared to the same period in 2022. The company saw substantial growth in the U.S. heart failure business, driven by increased adoption of Barostim. Gross profit and gross margin also improved significantly.

CVRx reported a strong fourth quarter and full year 2022, with revenue increasing by 96% in Q4 compared to the prior year. The growth was primarily driven by the U.S. heart failure business, with increased adoption of Barostim and expansion into new sales territories.

CVRx reported strong financial results for Q3 2022, with revenue increasing by 82% compared to the prior year. U.S. revenue saw a substantial increase of 96%, driven by growth in the heart failure segment. The company is also progressing with its BeAT-HF clinical trial and expects to share data in the first half of 2023.

CVRx announced its financial results for the second quarter of 2022, highlighted by a 61% increase in revenue compared to the prior year, driven by growth in the U.S. market. The company also achieved a higher gross margin and received FDA approval for a new programmer and MR conditional labeling for its Barostim device.

CVRx reported a significant increase in revenue for Q4 2021, driven by the successful launch of Barostim for heart failure in the United States. Total revenue was $3.7 million, a 75% increase compared to the same period in the prior year. The company is focused on driving accelerated adoption by executing on its commercial strategy, which includes the continued expansion of its salesforce and the efforts to educate healthcare providers and consumers on the benefits of Barostim.

CVRx reported a 241% increase in revenue for the third quarter of 2021, reaching $3.4 million, driven primarily by growth in the U.S. heart failure business. The company's gross profit also saw a substantial increase, while operating expenses rose due to increased headcount and marketing activities. The company continues to expect revenue between $3.9 million and $4.5 million for the fourth quarter of 2021.